Want to see OTLK full AI Analyst Report?
OTLK Stock Chart & Stats
$0.64
-$0.07(-5.34%)
At close: 4:00 PM EDT
$0.64
-$0.07(-5.34%)
Day’s Range― - ―
52-Week Range$0.16 - $2.54
Previous CloseN/A
Volume462.68K
Average Volume (3M)4.23M
Market Cap
$113.96M
Enterprise Value$224.61M
Total Cash (Recent Filing)$11.24M
Total Debt (Recent Filing)$18.43M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Dec 18, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding243,447,560
10 Day Avg. Volume3,421,183
30 Day Avg. Volume4,228,363
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.84
Price to Sales (P/S)19.10
P/FCF Ratio-0.52
Enterprise Value/Market Cap1.97
Enterprise Value/Revenue-193.10
Enterprise Value/Gross Profit-98.70
Enterprise Value/Ebitda-3.61
Forecast
1Y Price Target
$7.25Price Target Upside1032.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$44.06M
Bulls Say, Bears Say
Bulls Say
FDA-approved Lead ProductFDA approval converts LYTENAVA from a development-stage candidate into a commercially viable product with a differentiated regulatory position. That status can support physician confidence, payer discussions, and adoption over the next several quarters while establishing a platform for broader retinal commercialization.
Clinical EfficacyThe registrational efficacy result provides a durable clinical selling point rather than relying only on pricing or market access. A stronger response profile can improve commercial messaging, help differentiate LYTENAVA from alternatives, and support sustained physician interest during launch execution.
Large Addressable MarketA large established treatment market and substantial use of repackaged bevacizumab create a meaningful conversion opportunity for an FDA-approved alternative. This gives Outlook a sizeable commercial foundation and allows growth to come from switching existing treatment demand, not only from expanding the overall market.
Bears Say
Persistent UnprofitabilityPersistent large losses show that the business has not yet demonstrated operating leverage or self-funding economics. Even with commercialization underway, the company must scale revenue substantially before fixed costs and launch investments are absorbed, leaving earnings dependent on successful product adoption.
Stressed Balance SheetNegative equity and sharply higher debt reduce financial flexibility at a critical commercialization stage. The weak capital cushion can constrain investment choices, increase dependence on external funding, and make the company more vulnerable if launch revenue develops more slowly than planned.
Competitive Pricing PressureIntense competition can limit LYTENAVA’s pricing power and make conversion from lower-cost compounded or biosimilar options difficult. Tender pressure and alternative therapies may compress gross economics, requiring strong clinical differentiation and efficient commercialization to achieve the planned revenue opportunity.
Outlook Therapeutics News
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.16 and its highest was $2.54 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $113.96M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Dec 18, 2026 which is in 47 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on Aug 14, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.01.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 243,447,560 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went down -14.865%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outlook Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.25 (1032.81% Upside)
$7.25 (1032.81% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 83%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Increased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.25%
12-Months-Change
Fundamentals
Return on Equity
222.01%
Trailing 12-Months
Asset Growth
16.94%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
OTLK Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive tone based on a transformational FDA approval, strong registrational efficacy data, clear commercial planning and recent financing to fund the U.S. launch. However, material risks remain: competitive pricing pressure from biosimilars, European commercialization challenges, reimbursement and patient affordability concerns, reliance on a J‑code and near‑term liquidity that required a public offering. Management positions the company to execute a measured launch with conservative forecasts and contingency upside if compounded bevacizumab availability changes.View all OTLK earnings summariesOTLK Stock 12 Month Forecast
Average Price Target
$7.25
▲(1032.81% Upside)
Technical Analysis
Ownership Overview
10.51% Insiders
2.17% Mutual Funds
0.41% Other Institutional Investors
83.29% Public Companies and
Individual Investors